Results 91 to 100 of about 449,138 (190)
C-elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging [PDF]
, 2008 Inclusions in the brain containing alpha-synuclein are the pathological hallmark of Parkinson's disease, but how these inclusions are formed and how this links to disease is poorly understood.
AA Cooper +38 more
core +8 more sources
Additional file 4: of Blood transcriptomics of drug-naĂŻve sporadic Parkinsonâ s disease patients
, 2015 Square of the Mahalanobis distance calculated for each sample from both control and pathological class models. (PDF 3122 kb)
Calligaris, Raffaella +17 more
openaire +1 more source
Immunogenicity Associated with Botulinum Toxin Treatment
Toxins, 2019 Botulinum toxin (BoNT) has been used for the treatment of a variety of neurologic, medical and cosmetic conditions. Two serotypes, type A (BoNT-A) and type B (BoNT-B), are currently in clinical use. While considered safe and effective, their use has been
Steven Bellows, Joseph Jankovic
doaj +1 more source
Changes in structural network topology correlate with severity of hallucinatory behavior in Parkinson's disease [PDF]
, 2019 Inefficient integration between bottom-up visual input and higher order visual processing regions is implicated in visual hallucinations in Parkinson's disease (PD). Here, we investigated white matter contributions to this perceptual imbalance hypothesis.
Hall, Julie +7 more
core +2 more sources
MOESM2 of Prevalence and incidence of Parkinsonâ s disease and drug-induced parkinsonism in Korea
, 2019 Additional file 2: Figure S1. Sensitivity analysis. Incidence of drug-induced parkinsonism in Korea.
Sola Han +5 more
openaire +1 more source
Unsupervised Parkinson’s Disease Assessment [PDF]
, 2018 Parkinson’s Disease (PD) is a progressive neurological disease that affects 6.2 million people worldwide. The most popular clinical method to measure PD tremor severity is a standardized test called the Unified Parkinson’s Disease Rating Scale (UPDRS ...
Adranly, Alexander S. +2 more
core +1 more source
Parkinson's disease dementia: a neural networks perspective. [PDF]
, 2015 In the long-term, with progression of the illness, Parkinson's disease dementia affects up to 90% of patients with Parkinson's disease. With increasing life expectancy in western countries, Parkinson's disease dementia is set to become even more ...
Foltynie, T, Gratwicke, J, Jahanshahi, M
core +1 more source
, 2019 Additional file 4. Table with secondary outcomes of PDQ-carer.
K. Hannink +8 more
openaire +1 more source
Pilot and Feasibility Studies, 2019 Background One of the greatest barriers found by physical therapy treating individuals with Parkinson’s disease (PD) is the adherence to treatment, associated with the lack of motivation to remain active.
Helena de Oliveira Braga +7 more
doaj +1 more source
, 2015 Additional file 2: Table S1. Brain regions with gray matter volume reduction in the patients with Parkinsonâ s disease compared with the healthy control group.
Wei-Che Lin +12 more
openaire +1 more source